NEW HOPE, Pa., Nov. 29, 2016 /PRNewswire/ -- BackBeat Medical Inc., a medical technology company developing novel cardiac stimulation-based therapies for hypertension and heart failure, today announced that clinical data for the company's patented Programmable Hypertension Control (PHC) therapy will be presented at the Innovations in Cardiovascular Interventions (ICI) Meeting 2016, Dec. 4-6, in Tel Aviv, Israel.
The presentation will feature results from the first-in-man study of BackBeat's PHC therapy including two years of follow-up data from patients who received BackBeat's Moderato™ pacemaker incorporating the company's proprietary pacing algorithms. Dr. Yuval Mika, CEO and co-founder, will deliver the presentation "Programmable Hypertension Control (PHC) - A Pacemaker-Mediated Novel Approach for the Treatment of Hypertension" during the session "Technology Parade I - Devices" at 9:50 a.m. IST on Monday, Dec. 5 in Room 4 at the David Intercontinental Convention Center.
About BackBeat Medical
BackBeat Medical Inc. is a medical technology company founded in 2010 to develop novel cardiac stimulation-based therapies for hypertension and heart failure. BackBeat has developed a patented cardiac pacing-based treatment for hypertension (HTN) called programmable hypertension control (PHC) therapy. PHC is comprised of proprietary pacing algorithms that can be readily incorporated into standard pacemakers using standard leads and standard lead placement and thus has broad applicability. PHC offers a new potent device-based HTN therapeutic alternative potentially opening up a large market to treat HTN patients, particularly HTN patients who already have or require a pacemaker. Clinical results generated to date using BackBeat's own Moderato™ pacemaker incorporating PHC algorithms demonstrate that this therapy has a substantial and sustained therapeutic effect on blood pressure as determined by both in-office cuff measurements (average reduction of 24 mmHg from baseline) and 24-hour ambulatory measurements (average reduction of 14 mmHg from baseline) with clinical follow up extending up to two years.
SOURCE BackBeat Medical Inc.